We're investing over £280,000 to accelerate the development of new Parkinson's drugs
Date
News
Date
UCB, a global pharmaceutical company, has joined forces with Parkinson's UK, and the Parkinson's Foundation in the US, to establish a Patient Engagement Council for Parkinson's Research.
Date
We've launched a new report, Nobody really knows us – the state of health and social care for people with Parkinson's-related dementia.
Date
We've developed an interactive communications toolkit to help researchers in all areas of health research to keep in touch with their participants. It is supported by the Health Research Authority (HRA) as part of the Make It Public strategy.
Date
We've invested a further £490,000 to support the development of drugs to protect mitochondria and treat Parkinson's.
Date
Results show that atomoxetine, a drug used to treat attention deficit hyperactivity disorder (ADHD), could improve thinking and impulsiveness in Parkinson's.
Date
Researchers in the United States have shown that a compound found in fruit - farnesol - has the potential to play a protective role to dopamine-producing brain cells.
Date
Caroline Rassell has been appointed as our new Chief Executive. She brings 20 years of board experience in healthcare and government roles.
Date
New research has been published that sheds an important light on how the production of a key protein in the brain is controlled This could pave the way for new treatments for a wide range of neurological conditions.
Date
Over 30 Scottish landmarks, including Edinburgh Castle, showed their support by lighting up in the colours of Parkinson's UK
Date
It's our mission to improve life for everybody affected by Parkinson's. To stay true to this, we must proactively tackle barriers to accessing our support and NHS services, and barriers to participating in medical research.